Business Wire

Ricardo Commissioned to Define a Single Harmonised European Life Cycle Assessment Standard for Zero Emission Vehicles and Batteries

15.2.2023 03:01:00 EET | Business Wire | Press release

Share

Ricardo, a global strategic environmental and engineering consulting company, has commenced a European Union-funded project to develop a baseline for a European-wide commonly accepted and applied single life cycle assessment (LCA) approach for zero emission vehicles (ZEV) and batteries based on evidence and real-world data. This initiative is a Coordination and Support Action supported under the Horizon Europe Framework Programme and has also received funding from UK Research and Innovation (UKRI).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005551/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Electric car and truck charging (Photo: Business Wire)

Currently, there is no agreed European or international standard on vehicle life cycle assessment, although there are a number of standards in draft or being developed for electric vehicle (EV) batteries. Defining a single, harmonised life cycle assessment approach for vehicles and batteries is key to providing transparency and comparability of impacts from these products. This will help to achieve Green Deal targets, making Europe the first digitally enabled circular, climate-neutral and sustainable economy. Harmonised standards will facilitate industry, mobility providers and planners to develop sustainable road transport products that are optimised to combat climate change. Ricardo is on the core team of the collaborative TranSensus LCA consortium – jointly coordinated by the Fraunhofer Institute for Structural Durability and System Reliability LBF and the Fraunhofer-Institution of Surface Engineering and Thin Films IST– which comprises 44 stakeholders from industry and research along the full value chain of zero emission vehicles and batteries including: research institutions, vehicle and battery manufacturers, the supply industry, energy providers and recyclers.

Nikolas Hill, Head of Vehicle Technologies and Fuels in Ricardo’s Sustainable Transport team said: “The major report on life cycle impacts of road vehicles that Ricardo undertook for the European Commission in 2020 highlighted the importance of life cycle assessment in sustainable product and business development, but also the challenges for its application. In particular, efforts fully to use and realise the benefits from life cycle assessment approaches by the transport sector are being hampered because there is not an official European standard for vehicle LCA. This is largely because of a lack of a consistent, fair framework or harmonised methodology, plus limitations in accessing and managing real-world data and applying consistent modelling. Through our work with our industry and research partners on this project, Ricardo policy, strategy and technology experts will help to deliver a standard, trustworthy and consistent assessment of full vehicular environmental footprints, to support organisations across the transport value chain progress their objective of achieving climate neutrality.”

Ricardo’s 2020 report for the European Commission, DG Climate Action: Determining the environmental impacts of conventionally and alternatively fuelled vehicles through LCA was the broadest and most comprehensive study of its kind to date. The report assessed the life cycle impacts of 65 different European light- and heavy-duty vehicle types and powertrain combinations. It considered the production of 60 fuel chains for conventional and alternative fuels as well as 14 different forms of electricity generation, the impacts of vehicle (and battery) manufacturing, and vehicle use and maintenance including different ‘end of life’ scenarios. The report also highlighted the positive impact of existing European Union policy in directly supporting the move to a more circular economy and the initiatives aimed at developing a sustainable value chain for hybrid and fully electric vehicles and their batteries in driving down industrial emissions and improving resource efficiency.

Ends

Notes to editors:

TranSensus LCA is funded by the European Union under the Grant Agreement #101056715. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or CINEA. Neither the European Union nor the granting authority can be held responsible for them.

About Ricardo

Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye